Trial Profile

A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab-(MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 05 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Favezelimab (Primary) ; Lenvatinib (Primary) ; Pembrolizumab (Primary) ; Quavonlimab (Primary)
Indications Non-small cell lung cancer
Focus Biomarker; Therapeutic Use
Acronyms KeyImPaCT; KEYNOTE-495
Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

26 Feb 2025 Planned End Date changed from 28 Jun 2025 to 3 Nov 2025.
26 Feb 2025 Planned primary completion date changed from 28 Jun 2025 to 3 Nov 2025.
01 Jul 2023 Interim Results assessing the safety and efficacy of Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancerpublished in the Nature Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com